Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

AZD-7762

HY-10992

(AZD7762; AZD 7762)

AZD-7762

AZD-7762 Chemical Structure

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM; equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $79 In-stock
5 mg $72 In-stock
10 mg $110 In-stock
50 mg $358 In-stock
100 mg $468 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €77 In-stock
5 mg €71 In-stock
10 mg €108 In-stock
50 mg €351 In-stock
100 mg €459 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: AZD-7762
Cat. No.: HY-10992

AZD-7762 Data Sheet

  • View current batch:

    Purity: 99.74% ee.:99.89%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

    Pdf Version

    NMR

    Pdf Version

    LCMS

Customer View

Related Compound Libraries

Biological Activity of AZD-7762

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM; equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck.
IC50 Value: 5 nM
Target: ChK
in vitro: AZD-7762 is a novel checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2, respectively. AZD7762, a more selective Chk1 inhibitor, inhibits Chk1 phosphorylation of a cdc25C peptide by reversibly binding to the ATP-binding site of Chk1, with IC50 of 5 nM and Ki of 3.6 nM. AZD7762 induces cell arrest with EC50 of 0.620 μM, and significantly abrogates the camptothecin induced G2 arrest with an EC50 of 10 nM, by blocking the chk1 dependent degradation of Cdc25A and activation of Cyclin A. AZD7762 (300 nM) enhances the antitumor efficacy of gemcitabine against SW620 and topotecan against MDA-MB-231 by reducing the GI50 values from 24.1 nM and 2.25 μM to 1.08 nM and 0.15 μM, respectively. AZD7762 shows cytotoxicity against a variety of neuroblastoma cell lines bearing p53 wild type, p53 mutation, Mdm2 amplification or p14 deletion with IC50 values ranging from 82.6-505.9 nM.
in vivo: AZD-7762 significantly prolonged the median time required for tumor volume doubling in response to gemcitabine and radiation. AZD7762 alone at 25 mg/kg shows little antitumor activity in the H460-DNp53 xenograft mice and SW620 xenograft mice, but when administrated in combination with gemcitabine (60 mg/kg), AZD7762 shows significant antitumor efficacy in the two xenografts mice with a log cell kill of 0.9 or percent treated/control (%T/C) of 26 even at low dose of 12.5 mg. Dosing of AZD7762 in combination with gemcitabine (10 mg/kg) in the H460-DNp53 xenograft rat inhibits the tumor volume in a dose-dependent manner with the %T/C values of 48 and 32 for 10 and 20 mg/kg AZD7762, respectively. AZD7762 (25 mg/kg) in combination with irinotecan (25 or 50 mg/kg) causes complete tumor regression in the SW620 xenograft mice with the %T/C increasing significantly to -66% and -67%, respectively.

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 362.42 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C17H19FN4O2S
CAS No 860352-01-8
Solvent & Solubility

DMSO ≥70mg/mL Water <1.2mg/mL Ethanol ≥2.6mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.7592 mL 13.7961 mL 27.5923 mL
5 mM 0.5518 mL 2.7592 mL 5.5185 mL
10 mM 0.2759 mL 1.3796 mL 2.7592 mL

References on AZD-7762

Inhibitor Kit

Related Checkpoint Kinase (Chk) Products

  • BML-277

    BML-277 (C 3742) is a selective Chk2 (checkpoint kinase 2) inhibitor with an IC50 of 15 nM.

  • CHIR-124

    CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM; 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.

  • LY2603618

    LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials.

  • PF 477736